Pharmacotherapy of obesity
Pharmacotherapy of obesity
复制标题
DOI：
10.1016/j.clindermatol.2004.01.008
复制
发表时间：
2004-07-01
影响因子：
2.7
通讯作者：
Rössner, S
中科院分区：
文献类型：
--
作者：
Linné, Y;Rössner, S
尽管在过去的30年里已经开发了几种治疗大多数其他慢性疾病的药物，但肥胖症的药物治疗进展缓慢。(1)药物治疗肥胖症的记录部分解释了这一现象，令人担忧。当发现严重的副作用时，一些化合物已经被撤回。（2，3）缺乏科学开发的安全有效的减肥药物已经为大量的商业产品打开了大门，这些产品可以赚大钱，但没有科学证据支持它们的功效。发达国家和发展中国家都有这种模式。表1总结了一些目前公认的，经过科学评估的减肥药。目前，奥利司他和西布曲明是仅有的两种几乎全世界使用的主要药物。
Whereas several drugs to treat most other chronic conditions have been developed over the last 30 years, progress in pharmacologic therapy for obesity has been slow.(1) The record of drug treatment for obesity partly explains this phenomenon and is of concern. Several compounds have been withdrawn when severe side effects have been discovered.(2,3) The lack of scientifically developed safe and effective antiobesity drugs has opened the gates for an enormous number of commercial products that make vast sums of money, but have no scientific evidence backing their efficacy. This pattern is seen in both developed and developing countries. Table 1 summarizes some of the presently accepted, scientifically evaluated antiobesity drugs. At present, orlistat and sibutramine are the only two major drugs used almost worldwide.